JP5443168B2 - {2−[1−(3,5−ビス−トリフルオロメチル−ベンジル)−5−ピリジン−4−イル−1h−[1,2,3]トリアゾール−4−イル]−ピリジン−3−イル}−(2−クロロフェニル)−メタノンの調製において有用な新規の中間体及び方法 - Google Patents
{2−[1−(3,5−ビス−トリフルオロメチル−ベンジル)−5−ピリジン−4−イル−1h−[1,2,3]トリアゾール−4−イル]−ピリジン−3−イル}−(2−クロロフェニル)−メタノンの調製において有用な新規の中間体及び方法 Download PDFInfo
- Publication number
- JP5443168B2 JP5443168B2 JP2009543027A JP2009543027A JP5443168B2 JP 5443168 B2 JP5443168 B2 JP 5443168B2 JP 2009543027 A JP2009543027 A JP 2009543027A JP 2009543027 A JP2009543027 A JP 2009543027A JP 5443168 B2 JP5443168 B2 JP 5443168B2
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- methanone
- chlorophenyl
- hydroxy
- vinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 26
- -1 3,5-Bis-trifluoromethyl-benzyl Chemical group 0.000 title claims description 16
- 238000002360 preparation method Methods 0.000 title description 15
- 239000000543 intermediate Substances 0.000 title description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 35
- 239000013078 crystal Substances 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 18
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 18
- 229940011051 isopropyl acetate Drugs 0.000 claims description 16
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 16
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical group OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 11
- GMNRLJOAZMNQMK-UHFFFAOYSA-N (2-chlorophenyl)-[2-(2-hydroxy-2-pyridin-4-ylethenyl)pyridin-3-yl]methanone Chemical compound C=1C=NC=CC=1C(O)=CC1=NC=CC=C1C(=O)C1=CC=CC=C1Cl GMNRLJOAZMNQMK-UHFFFAOYSA-N 0.000 claims description 10
- LPNBBFKOUUSUDB-UHFFFAOYSA-N p-toluic acid Chemical compound CC1=CC=C(C(O)=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-N 0.000 claims description 10
- BCYBZAQWIMJEOI-UHFFFAOYSA-N benzoic acid (2-chlorophenyl)-[2-(2-hydroxy-2-pyridin-4-ylethenyl)pyridin-3-yl]methanone Chemical compound OC(=O)C1=CC=CC=C1.C=1C=NC=CC=1C(O)=CC1=NC=CC=C1C(=O)C1=CC=CC=C1Cl BCYBZAQWIMJEOI-UHFFFAOYSA-N 0.000 claims description 9
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 8
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000011877 solvent mixture Substances 0.000 claims description 5
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 36
- 239000000203 mixture Substances 0.000 description 26
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 239000007787 solid Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 235000021317 phosphate Nutrition 0.000 description 6
- 238000005498 polishing Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- JKGHUBCPWOLOFQ-UHFFFAOYSA-N 1-(azidomethyl)-3,5-bis(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(CN=[N+]=[N-])=CC(C(F)(F)F)=C1 JKGHUBCPWOLOFQ-UHFFFAOYSA-N 0.000 description 5
- CAVRKWRKTNINFF-UHFFFAOYSA-N [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-3-yl]-(2-chlorophenyl)methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(=C(N=N2)C=2C(=CC=CN=2)C(=O)C=2C(=CC=CC=2)Cl)C=2C=CN=CC=2)=C1 CAVRKWRKTNINFF-UHFFFAOYSA-N 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- MPTVNPMFAZVTJG-UHFFFAOYSA-N 2-(benzenesulfonyl)pyridine Chemical compound C=1C=CC=NC=1S(=O)(=O)C1=CC=CC=C1 MPTVNPMFAZVTJG-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
- OINTXXMBRBLMHH-UHFFFAOYSA-N 1-(chloromethyl)-3,5-bis(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(CCl)=CC(C(F)(F)F)=C1 OINTXXMBRBLMHH-UHFFFAOYSA-N 0.000 description 3
- WMQUKDQWMMOHSA-UHFFFAOYSA-N 1-pyridin-4-ylethanone Chemical compound CC(=O)C1=CC=NC=C1 WMQUKDQWMMOHSA-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CQFZPZLDLNMGAW-UHFFFAOYSA-N [2-(benzenesulfonyl)pyridin-3-yl]-(2-chlorophenyl)methanone Chemical compound ClC1=CC=CC=C1C(=O)C1=CC=CN=C1S(=O)(=O)C1=CC=CC=C1 CQFZPZLDLNMGAW-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102000007124 Tachykinin Receptors Human genes 0.000 description 2
- 108010072901 Tachykinin Receptors Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 239000012455 biphasic mixture Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 231100000707 mutagenic chemical Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000005292 vacuum distillation Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KFPMDNNVMQLXCF-UHFFFAOYSA-N (2-chlorophenyl)-[2-(2-hydroxy-2-pyridin-4-ylethenyl)pyridin-3-yl]methanone phosphoric acid Chemical compound P(=O)(O)(O)O.ClC1=C(C=CC=C1)C(=O)C=1C(=NC=CC1)C=C(C1=CC=NC=C1)O KFPMDNNVMQLXCF-UHFFFAOYSA-N 0.000 description 1
- RVWUHFFPEOKYLB-UHFFFAOYSA-N 2,2,6,6-tetramethyl-1-oxidopiperidin-1-ium Chemical compound CC1(C)CCCC(C)(C)[NH+]1[O-] RVWUHFFPEOKYLB-UHFFFAOYSA-N 0.000 description 1
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical compound ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 description 1
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010069632 Bladder dysfunction Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 229910020366 ClO 4 Inorganic materials 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 229910019093 NaOCl Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- GMNRLJOAZMNQMK-LDADJPATSA-N O/C(/c1ccncc1)=C/c1ncccc1C(c(cccc1)c1Cl)=O Chemical compound O/C(/c1ccncc1)=C/c1ncccc1C(c(cccc1)c1Cl)=O GMNRLJOAZMNQMK-LDADJPATSA-N 0.000 description 1
- NDXHGLYPKXEZEB-UHFFFAOYSA-N O=C(Cc1ncccc1C(c(cccc1)c1Cl)=O)c1ccncc1 Chemical compound O=C(Cc1ncccc1C(c(cccc1)c1Cl)=O)c1ccncc1 NDXHGLYPKXEZEB-UHFFFAOYSA-N 0.000 description 1
- 0 OC(c1ccncc1)=Cc1ncccc1*(c1ccccc1Cl)=O Chemical compound OC(c1ccncc1)=Cc1ncccc1*(c1ccccc1Cl)=O 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- JTBVPHBMCXEPOX-UHFFFAOYSA-N benzoic acid;formaldehyde Chemical compound O=C.OC(=O)C1=CC=CC=C1 JTBVPHBMCXEPOX-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 229910000856 hastalloy Inorganic materials 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 238000010949 in-process test method Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- WCFMYNWLLNSYBH-UHFFFAOYSA-N sodium 1-(azidomethyl)-3,5-bis(trifluoromethyl)benzene azide Chemical compound [N-]=[N+]=[N-].[Na+].N(=[N+]=[N-])CC1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F WCFMYNWLLNSYBH-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- CGRKYEALWSRNJS-UHFFFAOYSA-N sodium;2-methylbutan-2-olate Chemical compound [Na+].CCC(C)(C)[O-] CGRKYEALWSRNJS-UHFFFAOYSA-N 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
反応器Aに粉末状のKOtBu(221.1g、1.93モル、1.40当量)を添加し、25℃で10分間にわたり、DMSO(2L)を添加した。KOtBu/DMSO溶液を23℃で30分間撹拌し、次に、DMSO(250mL)中に4−アセチルピリジン(92mL、2.07モル、1.50当量)を含有する溶液を反応器Bで調製した。反応器Bの内容物を10分間にわたり反応器Aに添加し、反応器Aのエノラート溶液を23℃で1時間撹拌した。別の12Lフラスコ(反応器C)において、固体状のLiOH(84.26g、3.45モル、2.0当量)を、23℃で撹拌しながら、(2−フェニルスルホニル−ピリジン−3−イル)−(2−クロロフェニル)メタノン(500.0g、1.34モル、1.0当量)とDMSO(2L)の混合液に注いだ。反応器A中のエノラート溶液を次に、少なくとも15分間にわたり反応器Cに添加し、赤い懸濁液を40℃に加熱した。反応液を3時間撹拌し、その後HPLC分析した結果、2%未満の(2−フェニルスルホニル−ピリジン−3−イル)−(2−クロロフェニル)メタノン含量であった。トルエン(2.5L)を添加し、反応器温度を30℃に冷却した。混合物中に氷酢酸(316mL、5.52モル、4.0当量)、続いて10%のNaCl(2.5L)を添加してクエンチした。二相混合物を、底に出口を有する22Lのモートンフラスコへ移し、水層を除去した。水層を次に、トルエン(750mL)で抽出した。合わせた有機層を10%のNaCl(750mL)で洗浄し、次に4容量に濃縮し、12Lのモートンフラスコへ移し、イソプロピルアセテート(4容量、2L)で洗浄した。不透明な琥珀色の溶液を、40分間にわたり、75℃に加温した。安息香酸(171.1g、1.34モル、1.0当量)を、加熱したイソプロピルアセテート(1.5L)中に溶解させ、少なくとも30分間にわたり、粗製の遊離塩基溶液に添加した。安息香酸塩を含有する粗製の溶液を75℃で0.5時間撹拌し、次に23℃に冷却した。固体が観察されはじめたとき冷却を停止し、結晶が最初に観察された当該温度で混合物を1時間静置した。あるいは、種結晶が利用できる場合、(2−クロロフェニル)−[2−(2−ヒドロキシ−2−ピリジン−4−イル−ビニル)ピリジン−3−イル]メタノン安息香酸塩(2.25g)を用いて75℃で混合物に種結晶添加し、次に75℃で0.5時間撹拌し、次に少なくとも1.5時間かけて、23℃に冷却してもよい。次に混合物を<5℃に冷却し、次に24cmの1枚プレートのフィルタ上の紙を通して濾過した。濾過ケーキを次に冷却したi−PrOAc(750mL)で洗浄し、明るいオレンジ色−赤色の粒状の結晶を得た。湿固体を55℃で乾燥させ、99.9%の純度で527.3g(83%の収率)を得た。(2−クロロフェニル)−[2−(2−ヒドロキシ−2−ピリジン−4−イル−ビニル)ピリジン−3−イル]メタノン安息香酸塩。C26H19N2ClO4の計算値:C,68.05、H,4.17、N,7.13。実測値:C,67.89、H,4.15、N,6.05。HRMS:C19H13ClN2O2の計算値:336.0666、実測値:336.0673。
以下の点を除いて、調製1−Aに記載の手順に従い調製した。固体のトルイル酸(1.0当量)を、55℃で粗製の遊離塩基溶液に添加し、溶液を45℃に冷却した。溶液を45℃で1時間撹拌し、徐々に23℃に冷却した。固体が最初に観察されたときに冷却を停止し、結晶が最初に観察された温度で、混合物を1時間静置した。あるいは、種結晶が利用できる場合、混合物に種結晶を添加し、45℃で3時間静置し、4時間かけて0℃に冷却してもよい。単離されたスラリーを濾過し、ウェットケーキをMeOH(3容量)で洗浄した。ウェットケーキを50℃で乾燥させ、淡い赤色の粉末として(2−クロロフェニル)−[2−(2−ヒドロキシ−2−ピリジン−4−イル−ビニル)ピリジン−3−イル]メタノントルイル酸塩を14.0g(76.4%)得た。
5容量のTHF中に1.3当量のジイソプロピルアミン(2−ベンゼンスルホニルピリジンを主成分とする)の溶液を、3口フラスコ中で撹拌装置により撹拌しながら、−70〜−75℃に冷却した。この溶液に、−60℃未満の温度が維持される速度で、1.05当量のn−ブチルリチウム(ヘキサン中、1.6M)を添加した。淡い黄色の溶液を、−60〜−70℃で30分間撹拌した。温度を再び−60〜−65℃に戻した後、3容量のTHF中の溶液として、2−ベンゼン−スルホニルピリジン1.0当量を、反応温度を−60℃以下に維持する最も速い速度で添加した。添加する間、黄色の懸濁液が形成され、更に長く撹拌すると黄色−オレンジ色に変化した。この混合物を−60〜−75℃で3時間撹拌し、次に2−クロロベンズアルデヒド1.06当量(1容量のTHF中の溶液として)を、−55℃未満の温度を維持するのに充分な速度で、滴加した。上記懸濁液は徐々にオレンジ色−赤色に変化し、希薄になり、それから澄んだ赤色の溶液に変化した。反応混合物を−60〜−70℃で1時間撹拌し、3NのHCl水溶液(7容量)を20〜30分間にわたり添加した。発熱が生じ、温度が0〜10℃となった。色がかなり消失し、二相の黄色の溶液が残留した。溶液を、少なくとも10℃に加温し、層を分離させ、水層を10容量の酢酸エチルで逆抽出した。合わせた有機層を、10容量の飽和炭酸水素ナトリウム溶液で洗浄し、次に約2容量となるまで濃縮した。酢酸エチル(10容量)を添加し、溶液を再度、2容量に濃縮した。濃縮した溶液を一晩静置し、粗製の中間体アルコールを、精製せずに次のステップに供した。粗製の中間体アルコールを、十分量の酢酸エチルを有する3口フラスコへ移し、全体で10容量の溶液を調製した。黄色の溶液を、3.2容量の10%(w/w)臭化カリウム水溶液で処理し、続いて0.07当量の2,2,6,6−テトラメチルピペリジン−N−オキシド(TEMPO)で処理した。オレンジ色の混合物を0〜5℃に冷却し、12%(w/w)次亜塩素酸ナトリウム(9容量)中の1.25当量の重炭酸ナトリウム、及び5容量の水で30〜60分にわたり処理し、発熱させ、最高20℃まで温度を上昇させた。添加の間、混合物は暗褐色に変化したが、その後黄色の濃厚な沈殿が形成された。二相の淡い黄色の混合物を、周囲温度で1〜3時間撹拌し、その時点で、反応が全体的に終了した。二相混合物を0〜5℃に冷却し、その温度で3時間撹拌した。固体を濾過して除去し、4容量の冷却した酢酸エチルで洗浄し、続いて4容量の水で洗浄し、一定の重量となるまで45℃で真空乾燥した。典型的な収率は80〜83%であり、98%超の純度であった。1H NMR(600MHz,CDCl3−d)δppm7.38(td,J=7.52,1.28Hz,1H)7.47(dd,J=7.80,1.30Hz,1H)7.51(td,J=7.79,1.60Hz,1H)7.51(t,J=7.89Hz,2H)7.50−7.54(m,J=7.75,4.63Hz,1H)7.60(t,J=7.43Hz,1H)7.73(dd,J=7.75,1.60Hz,1H)7.81(dd,J=7.79,1.56Hz,1H)8.00(dd,J=8.44,1.10Hz,2H)8.76(dd,J=4.63,1.61Hz,1H)。
アジ化ナトリウム(74.3g、1.14モル)を水(125mL)中に懸濁させ、次にDMSO(625mL)を添加した。30分間撹拌した後、3,5−ビス(トリフルオロメチル)ベンジルクロライド(255.3g、0.97モル)及びDMSO(500mL)を含有する溶液を、30分間にわたり添加した。(3,5−ビス(トリフルオロメチル)ベンジルクロライドは、添加する前に35℃に加熱し、液化させた(MP=30〜32℃))。ベンジルクロライドを供給する容器をDMSO(50mL)で洗浄し、それをアジ化ナトリウム溶液に移し、混合物を40℃に加熱し、次に40℃で1時間維持し、それから23℃に冷却した。
反応混合物を1滴d6−DMSO中に溶解させ、メチレンシグナルの相対強度を積分した(3,5−ビス(トリフルオロメチル)ベンジルクロライドの0.35%の検出限界によるNMR確認)。
混合物が23℃となった後、ヘプタン(1500mL)で希釈し、更に水(1000mL)を添加し、発熱させ、ジャケットの設定温度23℃に対して混合物が35℃となった。水層を除去(〜2200mL)し、有機層(約1700mL)を水(750mL×2)で洗浄した。合わせた水層(〜3700mL)を分析し、廃棄した。
種結晶の粒径d90<20μm、種結晶の添加=0.1重量%、種結晶の添加温度=50℃、種結晶の静置時間=2時間、ヘプタン供給速度=2時間。他の好ましい実施形態では、種結晶の粒径はd90=40μm、種結晶添加温度=55℃、種結晶の添加=0.1〜2%である。
Claims (9)
- {2−[1−(3,5−ビストリフルオロメチルベンジル)−5−ピリジン−4−イル−1H−[1,2,3]トリアゾール−4−イル]−ピリジン−3−イル}−(2−クロロフェニル)−メタノンの結晶形IVを調製する方法であって、イソプロピルアセテート及びヘプタンの溶媒混合液から{2−[1−(3,5−ビストリフルオロメチルベンジル)−5−ピリジン−4−イル−1H−[1,2,3]トリアゾール−4−イル]−ピリジン−3−イル}−(2−クロロフェニル)−メタノンの結晶形IVを結晶化させるステップを有してなる調製方法。
- tert−ブタノールの存在下で、(2−クロロフェニル)−[2−(2−ヒドロキシ−2−ピリジン−4−イル−ビニル)ピリジン−3−イル]メタノンの塩を、1−アジドメチル−3,5−ビストリフルオロメチルベンゼンと反応させるステップを更に有し、{2−[1−(3,5−ビストリフルオロメチルベンジル)−5−ピリジン−4−イル−1H−[1,2,3]トリアゾール−4−イル]−ピリジン−3−イル}−(2−クロロフェニル)−メタノンを調製する、請求項1記載の方法。
- (2−クロロフェニル)−[2−(2−ヒドロキシ−2−ピリジン−4−イル−ビニル)ピリジン−3−イル]メタノンの塩が、安息香酸塩又はトルイル酸塩である、請求項2記載の方法。
- (2−クロロフェニル)−[2−(2−ヒドロキシ−2−ピリジン−4−イル−ビニル)ピリジン−3−イル]メタノンの塩が、安息香酸塩である、請求項3記載の方法。
- (2−クロロフェニル)−[2−(2−ヒドロキシ−2−ピリジン−4−イル−ビニル)ピリジン−3−イル]メタノン安息香酸塩及び(2−クロロフェニル)−[2−(2−ヒドロキシ−2−ピリジン−4−イル−ビニル)ピリジン−3−イル]メタノントルイル酸塩からなる群から選択される化合物。
- (2−クロロフェニル)−[2−(2−ヒドロキシ−2−ピリジン−4−イル−ビニル)ピリジン−3−イル]メタノン安息香酸塩である、請求項5記載の化合物。
- 45〜55℃でイソプロピルアセテート及びヘプタンの溶媒混合液から{2−[1−(3,5−ビストリフルオロメチルベンジル)−5−ピリジン−4−イル−1H−[1,2,3]トリアゾール−4−イル]−ピリジン−3−イル}−(2−クロロフェニル)−メタノンの結晶形IVを結晶化させる、請求項1記載の方法。
- 45〜55℃でイソプロピルアセテート及びヘプタンの溶媒混合液から{2−[1−(3,5−ビストリフルオロメチルベンジル)−5−ピリジン−4−イル−1H−[1,2,3]トリアゾール−4−イル]−ピリジン−3−イル}−(2−クロロフェニル)−メタノンの結晶形IVを結晶化させる、請求項2記載の方法。
- 45〜55℃でイソプロピルアセテート及びヘプタンの溶媒混合液から{2−[1−(3,5−ビストリフルオロメチルベンジル)−5−ピリジン−4−イル−1H−[1,2,3]トリアゾール−4−イル]−ピリジン−3−イル}−(2−クロロフェニル)−メタノンの結晶形IVを結晶化させる、請求項4記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87085106P | 2006-12-20 | 2006-12-20 | |
US60/870,851 | 2006-12-20 | ||
PCT/US2007/086319 WO2008079600A1 (en) | 2006-12-20 | 2007-12-04 | Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010513546A JP2010513546A (ja) | 2010-04-30 |
JP2010513546A5 JP2010513546A5 (ja) | 2011-01-27 |
JP5443168B2 true JP5443168B2 (ja) | 2014-03-19 |
Family
ID=39273082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009543027A Active JP5443168B2 (ja) | 2006-12-20 | 2007-12-04 | {2−[1−(3,5−ビス−トリフルオロメチル−ベンジル)−5−ピリジン−4−イル−1h−[1,2,3]トリアゾール−4−イル]−ピリジン−3−イル}−(2−クロロフェニル)−メタノンの調製において有用な新規の中間体及び方法 |
Country Status (22)
Country | Link |
---|---|
US (4) | US8772496B2 (ja) |
EP (1) | EP2121610B1 (ja) |
JP (1) | JP5443168B2 (ja) |
KR (1) | KR20090081028A (ja) |
CN (1) | CN101568523A (ja) |
AU (1) | AU2007337255A1 (ja) |
BR (1) | BRPI0721069A2 (ja) |
CA (1) | CA2671770C (ja) |
DK (1) | DK2121610T3 (ja) |
EA (1) | EA200970604A1 (ja) |
EC (1) | ECSP099441A (ja) |
ES (1) | ES2471990T3 (ja) |
HR (1) | HRP20140613T1 (ja) |
IL (1) | IL198775B (ja) |
MX (1) | MX2009006636A (ja) |
NO (1) | NO20092370L (ja) |
PL (1) | PL2121610T3 (ja) |
PT (1) | PT2121610E (ja) |
RS (1) | RS53386B (ja) |
SI (1) | SI2121610T1 (ja) |
WO (1) | WO2008079600A1 (ja) |
ZA (1) | ZA200903578B (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009006636A (es) * | 2006-12-20 | 2009-06-30 | Lilly Co Eli | Nuevos intermediarios y procesos utiles en la rpeparacion de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]tr iazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona. |
US10098859B2 (en) | 2012-09-05 | 2018-10-16 | Amri Ssci, Llc | Cocrystals of p-coumaric acid |
AU2016226006B2 (en) | 2015-03-04 | 2021-03-04 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
US10287287B2 (en) | 2015-08-17 | 2019-05-14 | Eli Lilly And Company | Process development of a pyridine-containing NK-1 receptor antagonist |
BR112020004964A2 (pt) | 2017-09-13 | 2020-09-15 | Vanda Pharmaceuticals Inc. | método que consiste em administrar uma quantidade de tradipitant eficaz, aperfeiçoamento, método aperfeiçoado para tratar um paciente que sofre de prurido ou dermatite atópica com tradipitant, e, métodos para tratar um paciente com prurido ou dermatite atópica, para selecionar e para determinar uma dosagem de tradipitant eficaz, para determinar que um paciente tem probabilidade de responder ao tratamento de dermatite atópica com tradipitant e para identificar um paciente. |
EP3710000A1 (en) * | 2017-11-17 | 2020-09-23 | Vanda Pharmaceuticals Inc. | Method of treatment of gastrointestinal diseases with tradipitant |
US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
EP3890735A1 (en) | 2018-12-03 | 2021-10-13 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
JP2023520369A (ja) * | 2020-03-26 | 2023-05-17 | バンダ・ファーマシューティカルズ・インコーポレイテッド | トラジピタントによる下気道感染症の治療 |
WO2023019084A1 (en) | 2021-08-12 | 2023-02-16 | Vanda Pharmaceuticals Inc. | Treatment of gastric accommodation with tradipitant |
WO2024138040A1 (en) | 2022-12-21 | 2024-06-27 | Vanda Pharmaceuticals Inc. | Methods of treatment with tradipitant |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20040600A1 (es) | 2002-04-26 | 2004-09-15 | Lilly Co Eli | Derivados de triazol como antagonistas del receptor de taquicinina |
US7381826B2 (en) * | 2003-10-24 | 2008-06-03 | Eli Lilly And Company | Crystalline forms of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
WO2006083711A1 (en) * | 2005-02-01 | 2006-08-10 | Eli Lilly And Company | Tachykinin receptor antagonists |
MX2009006636A (es) * | 2006-12-20 | 2009-06-30 | Lilly Co Eli | Nuevos intermediarios y procesos utiles en la rpeparacion de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]tr iazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona. |
-
2007
- 2007-12-04 MX MX2009006636A patent/MX2009006636A/es active IP Right Grant
- 2007-12-04 RS RS20140349A patent/RS53386B/en unknown
- 2007-12-04 AU AU2007337255A patent/AU2007337255A1/en not_active Abandoned
- 2007-12-04 JP JP2009543027A patent/JP5443168B2/ja active Active
- 2007-12-04 CA CA2671770A patent/CA2671770C/en active Active
- 2007-12-04 BR BRPI0721069-8A patent/BRPI0721069A2/pt not_active Application Discontinuation
- 2007-12-04 ES ES07865137.9T patent/ES2471990T3/es active Active
- 2007-12-04 CN CNA2007800466993A patent/CN101568523A/zh active Pending
- 2007-12-04 EA EA200970604A patent/EA200970604A1/ru unknown
- 2007-12-04 PL PL07865137T patent/PL2121610T3/pl unknown
- 2007-12-04 DK DK07865137.9T patent/DK2121610T3/da active
- 2007-12-04 PT PT78651379T patent/PT2121610E/pt unknown
- 2007-12-04 EP EP07865137.9A patent/EP2121610B1/en active Active
- 2007-12-04 KR KR1020097012894A patent/KR20090081028A/ko not_active Application Discontinuation
- 2007-12-04 US US12/515,794 patent/US8772496B2/en active Active
- 2007-12-04 WO PCT/US2007/086319 patent/WO2008079600A1/en active Application Filing
- 2007-12-04 SI SI200731483T patent/SI2121610T1/sl unknown
-
2009
- 2009-05-14 IL IL198775A patent/IL198775B/en active IP Right Grant
- 2009-05-22 ZA ZA200903578A patent/ZA200903578B/xx unknown
- 2009-06-17 EC EC2009009441A patent/ECSP099441A/es unknown
- 2009-06-22 NO NO20092370A patent/NO20092370L/no not_active Application Discontinuation
-
2014
- 2014-03-27 US US14/227,857 patent/US20140206877A1/en not_active Abandoned
- 2014-06-27 HR HRP20140613TT patent/HRP20140613T1/hr unknown
-
2015
- 2015-11-10 US US14/937,051 patent/US9708291B2/en active Active
-
2017
- 2017-06-15 US US15/623,550 patent/US10035787B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2009006636A (es) | 2009-06-30 |
NO20092370L (no) | 2009-09-16 |
US20160060250A1 (en) | 2016-03-03 |
AU2007337255A1 (en) | 2008-07-03 |
US9708291B2 (en) | 2017-07-18 |
IL198775B (en) | 2018-08-30 |
BRPI0721069A2 (pt) | 2014-02-04 |
KR20090081028A (ko) | 2009-07-27 |
RS53386B (en) | 2014-10-31 |
US8772496B2 (en) | 2014-07-08 |
US20100056795A1 (en) | 2010-03-04 |
EP2121610A1 (en) | 2009-11-25 |
CN101568523A (zh) | 2009-10-28 |
HRP20140613T1 (hr) | 2014-08-15 |
WO2008079600A1 (en) | 2008-07-03 |
PL2121610T3 (pl) | 2014-09-30 |
SI2121610T1 (sl) | 2014-08-29 |
US10035787B2 (en) | 2018-07-31 |
US20140206877A1 (en) | 2014-07-24 |
PT2121610E (pt) | 2014-06-25 |
ES2471990T3 (es) | 2014-06-27 |
US20170283394A1 (en) | 2017-10-05 |
CA2671770A1 (en) | 2008-07-03 |
EP2121610B1 (en) | 2014-04-02 |
ECSP099441A (es) | 2009-07-31 |
IL198775A0 (en) | 2010-02-17 |
JP2010513546A (ja) | 2010-04-30 |
EA200970604A1 (ru) | 2009-10-30 |
CA2671770C (en) | 2015-09-15 |
DK2121610T3 (da) | 2014-06-30 |
ZA200903578B (en) | 2010-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5443168B2 (ja) | {2−[1−(3,5−ビス−トリフルオロメチル−ベンジル)−5−ピリジン−4−イル−1h−[1,2,3]トリアゾール−4−イル]−ピリジン−3−イル}−(2−クロロフェニル)−メタノンの調製において有用な新規の中間体及び方法 | |
JP2010513546A5 (ja) | ||
CA2988594C (en) | Methods of making protein deacetylase inhibitors | |
JP5078993B2 (ja) | 1−(3,4−ジクロロベンジル)−5−オクチルビグアナイドまたはその塩の製造方法 | |
JP3269574B2 (ja) | メタノアントラセン化合物、これを含有する神経精神障害を治療するための調剤学的組成物、およびこの化合物を製造するための方法および中間体 | |
WO2005042515A1 (en) | Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone | |
CZ283485B6 (cs) | Způsob výroby látek, antagonisujících receptory fibrinogenu | |
JPS6110584A (ja) | イミダゾイソキノリン化合物およびその製造方法 | |
EP3619199B1 (en) | Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives | |
JPH04225975A (ja) | N−[3−(1h−イミダゾール−1−イル)フエニル]−4−(置換)−2−ピリミジナミン合成の改良法 | |
KR100574350B1 (ko) | 2-아미노피리딘 유도체의 제조방법 | |
CA2504796A1 (en) | Polymorphs of pantoprazole sodium salt and process for the preparation thereof | |
CN108586450B (zh) | 一种胆碱m受体抗结剂的重结晶纯化方法 | |
JP5323808B2 (ja) | フタロイルアムロジピンのアセトン溶媒和物 | |
EP1878737A1 (en) | Method for producing indazole-3-ylmethylphosphonium salt | |
JPH0674261B2 (ja) | キノロンカルボン酸誘導体 | |
WO1995000502A1 (fr) | Nouvel intermediare pour utilisation et traitement de synthese de production d'un derive d'aminopiperazine | |
JP2013508418A (ja) | 1−(4−((1r,2s,3r)−1,2,3,4−テトラヒドロキシブチル)−1h−イミダゾール−2−イル)エタノンを調製する方法 | |
CN107365299B (zh) | 一种达比加群酯的制备方法及其中间体 | |
CN115093399A (zh) | 一种抗痛风药物托匹司他的制备方法 | |
CN117658986A (zh) | Ar拮抗剂trc-253的制备方法 | |
CN114213255A (zh) | 一种六元环苄胺类化合物的合成方法 | |
JP3711625B2 (ja) | 1H−ピラゾロ[3,2−c]−1,2,4−トリアゾール系化合物の製造方法 | |
CN116396275A (zh) | 一种托匹司他的合成方法 | |
CN118206501A (zh) | 一种卢吗哌酮的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101201 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101201 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130611 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20130614 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130910 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130918 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131001 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131126 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131219 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5443168 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |